title: Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis.
abstract: Aortic valve stenosis (AVS) and coronary artery disease (CAD) are accompanied by changes in the cardiac extra cellular matrix (cECM) including the re-expression of oncofetal fibronectin (Fn) and tenascin-C (Tn-C) variants. Human antibodies against these variants are usable for targeted therapy. Aim of the study was the comparative analysis of cECM remodelling in tissue samples from right atrial auricle (RAA) and left ventricular septum (LVS). RAA and LVS specimens from 30 patients (17 × AVS; 13 × AVS+CAD) were analysed with respect to histological changes and ECM remodelling using PCR based ECM gene expression profiling. Re-expression of ED-A(+) Fn and A1(+) Tn-C was investigated on the mRNA and on the protein level. For immunofluorescence, human recombinant small immunoprotein (SIP) format antibodies were used. There was a positive correlation of the grade of histological changes in RAA and corresponding LVS samples (r = 0.695). ECM gene expression levels were higher in LVS compared to RAA. For 24 genes, a corresponding relevant (>2.5-fold) up- or down-regulation in RAA and LVS occurred. Using SIP antibodies, a positive correlation of protein deposition levels in RAA and corresponding LVS (r = 0.818) could be shown for ED-A(+) Fn. Cardiac tissue remodelling is likely a process involving the entire heart reflected by intra-individually comparable histology and cECM changes in RAA and LVS samples. ED-A(+) Fn might be an excellent target for an antibody-mediated delivery of diagnostic or therapeutic agents. The RAA is a valuable and representative tool to evaluate cardiac remodelling and to plan individualized therapy.
authors.affiliation: Department of Internal Medicine I, University Hospital of Jena, Erlanger Allee 101, 07740, Jena, Germany.
authors.forename: Anja
authors.initials: A
authors.lastname: Baldinger
authors.forename: Bernhard R
authors.initials: BR
authors.lastname: Brehm
authors.forename: Petra
authors.initials: P
authors.lastname: Richter
authors.forename: Torsten
authors.initials: T
authors.lastname: Bossert
authors.forename: Katja
authors.initials: K
authors.lastname: Gruen
authors.forename: Khosro
authors.initials: K
authors.lastname: Hekmat
authors.forename: Hartwig
authors.initials: H
authors.lastname: Kosmehl
authors.forename: Dario
authors.initials: D
authors.lastname: Neri
authors.forename: Hans-Reiner
authors.initials: HR
authors.lastname: Figulla
authors.forename: Alexander
authors.initials: A
authors.lastname: Berndt
authors.forename: Marcus
authors.initials: M
authors.lastname: Franz
mesh_terms: D000368:Aged; D001024:Aortic Valve Stenosis / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D003324:Coronary Artery Disease / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D005260:Female; D005353:Fibronectins / Q000235:genetics* / Q000378:metabolism; D020869:Gene Expression Profiling; D006325:Heart Atria / Q000378:metabolism* / Q000473:pathology; D006352:Heart Ventricles / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008297:Male; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019063:Tenascin / Q000235:genetics* / Q000378:metabolism; D014018:Tissue Distribution
chemical_list: D005353:Fibronectins; D012333:RNA, Messenger; D019063:Tenascin; C121542:oncofetal fibronectin